Epigenetic Dysregulation in Neurodegeneration

Epigenetic Dysregulation in Neurodegeneration

Overview

Epigenetic dysregulation is a unifying feature across Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and frontotemporal dementia (FTD). These modifications — DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA expression — regulate gene expression without altering the DNA sequence itself. In neurodegenerative diseases, the epigenetic machinery becomes perturbed by aging, environmental stress, and disease-specific protein aggregates, leading to widespread transcriptional changes that drive neuronal dysfunction and death. [@dejager2024]

This page provides a comprehensive cross-disease comparison of epigenetic alterations, focusing on the three pillars of epigenetic regulation: reader proteins (MeCP2, HDACs, BET proteins), writers and erasers (DNMTs, TETs, HATs, HDACs, HMTs), and downstream gene expression changes. It examines how each disease manifests specific epigenetic patterns and reviews emerging therapeutic strategies targeting the epigenome. [@fan2025]

Epigenetic Machinery: Architecture and Function

The epigenetic regulation system consists of three interconnected layers that collectively determine chromatin state and gene expression:

Writers: Enzymes That Add Epigenetic Marks

DNA Methyltransferases (DNMTs)

DNMTs catalyze the covalent addition of methyl groups to cytosine residues in CpG dinucleotides, establishing heritable gene silencing patterns. Three catalytically active DNMTs operate in the human genome:

Epigenetic Dysregulation in Neurodegeneration

Overview

Epigenetic dysregulation is a unifying feature across Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and frontotemporal dementia (FTD). These modifications — DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA expression — regulate gene expression without altering the DNA sequence itself. In neurodegenerative diseases, the epigenetic machinery becomes perturbed by aging, environmental stress, and disease-specific protein aggregates, leading to widespread transcriptional changes that drive neuronal dysfunction and death. [@dejager2024]

This page provides a comprehensive cross-disease comparison of epigenetic alterations, focusing on the three pillars of epigenetic regulation: reader proteins (MeCP2, HDACs, BET proteins), writers and erasers (DNMTs, TETs, HATs, HDACs, HMTs), and downstream gene expression changes. It examines how each disease manifests specific epigenetic patterns and reviews emerging therapeutic strategies targeting the epigenome. [@fan2025]

Epigenetic Machinery: Architecture and Function

The epigenetic regulation system consists of three interconnected layers that collectively determine chromatin state and gene expression:

Writers: Enzymes That Add Epigenetic Marks

DNA Methyltransferases (DNMTs)

DNMTs catalyze the covalent addition of methyl groups to cytosine residues in CpG dinucleotides, establishing heritable gene silencing patterns. Three catalytically active DNMTs operate in the human genome:

DNMT1 is the maintenance methyltransferase, responsible for copying existing methylation patterns onto the daughter strand during DNA replication. It preferentially binds hemimethylated DNA through its PCNA-interaction domain and ensures that methylation patterns are faithfully propagated through cell division. In neurons — which are largely post-mitotic — DNMT1 maintains methylation at regulatory elements and prevents aberrant activation of silenced regions. [@schneider2024]

In Alzheimer's disease, DNMT1 expression is significantly reduced in the prefrontal cortex and hippocampus, correlating with global hypomethylation and cognitive decline. Loss of DNMT1 leads to derepression of endogenous retroviruses and pro-inflammatory genes. [@chen2019]

In Parkinson's disease, DNMT1 and DNMT3A show altered activity in dopaminergic neurons of the substantia nigra pars compacta. Genetic studies have identified DNMT3A variants associated with increased PD risk. The balance between DNMT1 and DNMT3A determines whether specific gene promoters become hyper- or hypo-methylated. [@belpasando2012]

DNMT3A is the de novo methyltransferase that establishes new methylation patterns during cellular differentiation and in response to environmental signals. It is highly expressed in neurons, where it participates in activity-dependent DNA methylation changes at synaptic genes. DNMT3A knockout in mouse neurons leads to altered learning and memory, demonstrating its role in cognitive function. [@schneider2024]

DNMT3A mutations are associated with microcephaly and intellectual disability syndromes, and somatic mutations in DNMT3A are linked to clonal hematopoiesis, which increases AD risk through peripheral immune system effects. In ALS, DNMT3A dysregulation affects motor neuron survival, with some ALS-associated mutations impairing catalytic function. [@jones2024]

DNMT3B primarily functions during early development to establish methylation at pericentromeric satellite repeats. Its role in adult neurons is less prominent but may contribute to the maintenance of genomic stability.

Histone Methyltransferases (HMTs) and Demethylases (HDMs)

Histone methylation occurs on lysine and arginine residues, with outcomes that vary from activating (H3K4me3, H3K36me3) to repressive (H3K9me3, H3K27me3) depending on the site and degree of modification:

EZH2 (Enhancer of Zeste Homolog 2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), catalyzing H3K27me3 — a mark that recruits additional repressive complexes and compacts chromatin. EZH2 is elevated in AD microglia and contributes to repression of neuroprotective genes. Genetic or pharmacological inhibition of EZH2 reduces neuroinflammation in AD mouse models and promotes microglial transition toward a homeostatic state.

G9a (EHMT2) catalyzes H3K9me1/2, a mark associated with euchromatic gene silencing. G9a is increased in AD brain, repressing synaptic genes including BDNF and Glutamate Receptor GRIA1. G9a inhibition restores synaptic gene expression and improves cognitive function in APP/PS1 mice.

SUV39H1 maintains H3K9me3 at pericentromeric satellite regions. With aging, SUV39H1 activity declines, contributing to heterochromatin loss and transposable element reactivation.

LSD1 (KDM1A) is a flavin-dependent monoamine oxidase that removes H3K4me1/2 (activating) and H3K9me1/2 (repressive) marks, serving as a transcriptional co-regulator. LSD1 is altered in AD and PD, affecting neuronal gene expression programs.

JMJD3 (KDM6B) and UTX (KDM6A) are H3K27me2/3 demethylases. JMJD3 is induced by inflammatory stimuli in microglia, removing repressive H3K27me3 marks from pro-inflammatory gene promoters. In neurodegeneration, JMJD3 promotes neuroinflammation, making it a potential therapeutic target.

Histone Acetyltransferases (HATs)

HATs catalyze the addition of acetyl groups to lysine residues on histone tails, neutralizing their positive charge and reducing chromatin compaction. This open chromatin state facilitates transcription factor binding and active gene expression.

CBP (CREBBP) and p300 (EP300) are the primary HATs in neurons. They acetylate histones at active promoters and enhancers, particularly H3K27ac and H3K9ac. CBP/p300 are recruited by neuronal activity and synaptic signaling to regulate activity-dependent gene expression. Reduced CBP/p300 activity in AD correlates with impaired memory-related gene expression. Loss-of-function mutations in CBP cause Rubinstein-Taybi syndrome, characterized by intellectual disability.

GCN5 (KAT2A) and PCAF (KAT2B) are also involved in neuronal histone acetylation, though their roles in neurodegeneration are less characterized.

Erasers: Enzymes That Remove Epigenetic Marks

Histone Deacetylases (HDACs)

HDACs reverse histone acetylation, promoting chromatin compaction and transcriptional repression. There are four classes:

Class I HDACs (HDAC1, HDAC2, HDAC3, HDAC8) are primarily nuclear and ubiquitously expressed. HDAC1 and HDAC2 form the core of the CoREST and Sin3a repressive complexes. In AD brain, HDAC2 is elevated in the hippocampus and prefrontal cortex, where it represses synaptic plasticity genes including BDNF, Arc, and EGR1. [@gao2024]

Class IIa HDACs (HDAC4, HDAC5, HDAC7, HDAC9) can shuttle between nucleus and cytoplasm. They are highly expressed in neurons and regulate activity-dependent gene repression. HDAC4 translocates to the nucleus in AD, where it represses memory-related genes.

Class IIb HDACs (HDAC6, HDAC10) are primarily cytoplasmic, where HDAC6 deacetylates tubulin, Hsp90, and CFTR. HDAC6 inhibition has shown benefit in PD models by promoting alpha-synuclein clearance through autophagy.

Class III HDACs (SIRT1-SIRT7) are NAD+-dependent deacetylases and are discussed under "Metabolic Epigenetics" below.

Class IV HDAC (HDAC11) has roles in immune regulation, with emerging relevance to neuroinflammation.

DNA Demethylation Enzymes (TETs)

TET (Ten-Eleven Translocation) enzymes catalyze the stepwise oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). These oxidized derivatives are intermediates in active DNA demethylation and also function as stable epigenetic marks in their own right. [@zhao2024]

TET1 is highly expressed in neurons and is particularly enriched at gene bodies of actively transcribed genes. 5hmC is abundant in the brain, with levels 10-100 times higher than in other tissues. In AD, TET1 expression is altered, affecting the hydroxymethylation landscape.

TET2 is the most studied TET family member in neurodegeneration. TET2 loss-of-function mutations cause clonal hematopoiesis, a condition associated with increased AD risk due to inflammatory immune cell expansion. In the brain, TET2 regulates microglial gene expression and inflammatory responses.

TET3 is the dominant TET enzyme in oocytes and early development, but also functions in adult neurons where it contributes to activity-dependent demethylation.

Reader Proteins: Interpreting the Epigenetic Code

Reader proteins recognize and bind specific epigenetic marks, translating them into downstream molecular events. Key readers in neurodegeneration include:

MeCP2 (Methyl-CpG Binding Protein 2)

MeCP2 is a methyl-CpG-binding domain (MBD) protein that binds 5mC and 5hmC at methylated DNA and recruits transcriptional co-repressor complexes including SIN3A and HDAC1. Originally studied in the context of Rett syndrome, MeCP2 dysfunction is now recognized in multiple neurodegenerative conditions. [@matths2024]

MeCP2 structure and function: MeCP2 contains an MBD domain that binds symmetrically methylated CpGs, a transcriptional repression domain (TRD), and a C-terminal domain with multiple functions. MeCP2 can both repress and activate gene expression depending on context — it recruits HDAC complexes at methylated promoters but can also interact with CREB to enhance transcription at specific sites.

MeCP2 in Alzheimer's disease: Post-mortem studies of AD brain reveal altered MeCP2 phosphorylation and reduced binding to known target genes. MeCP2 regulates BDNF expression, and impaired MeCP2-BDNF signaling contributes to synaptic dysfunction in AD. [@matths2024]

MeCP2 in Parkinson's disease: MeCP2 is expressed in dopaminergic neurons and regulates genes involved in dopamine synthesis and transport. Altered MeCP2 activity may contribute to dopamine neuron vulnerability in PD.

MeCP2 in ALS/FTD: MeCP2 dysfunction has been reported in ALS motor neurons, where it may alter expression of genes involved in RNA metabolism — a process highly relevant to ALS pathogenesis.

BET Proteins (Bromo and Extra-Terminal)

Bromodomain and Extra-Terminal (BET) proteins — BRD2, BRD3, BRD4, and BRDT — recognize acetylated histones through their bromodomains and serve as transcriptional co-activators that recruit Mediator complex and RNA Polymerase II to active genes. [@chen2021]

BRD4 in Alzheimer's disease: BRD4 is elevated in AD brain and promotes transcription of pro-inflammatory genes in microglia and of amyloid-related genes in neurons. BET inhibition with JQ1 or its analogs reduces amyloid plaque burden and improves cognitive function in APP/PS1 and 5xFAD mouse models. BRD4 also regulates tau expression, and BET inhibitors reduce tau pathology in PS19 tauopathy mice.

BRD4 in ALS/FTD: BRD4 is implicated in C9orf72-linked ALS/FTD, where it may regulate aberrant transcription from the expanded hexanucleotide repeat. BET inhibition reduces toxic dipeptide repeat production in cellular models.

Additional Readers

MBT domain proteins (SFMBT1, L3MBTL1) recognize methylated lysines, particularly H3K9me1/2 and H3K27me1/2, and contribute to transcriptional repression.

Chromodomain proteins (HP1, CBX family) bind H3K9me3 and mediate heterochromatin maintenance. HP1alpha is reduced in AD brain, contributing to global chromatin relaxation. [@frost2014]

PHD fingers and Tudor domains recognize unmodified or specific methylated histones, further expanding the combinatorial complexity of the epigenetic code.

Chromatin Remodeling Complexes

Beyond covalent modifications, ATP-dependent chromatin remodelers alter nucleosome positioning to regulate chromatin accessibility. [@he2019]

SWI/SNF complexes use ATP hydrolysis to slide, evict, or restructure nucleosomes. The BAF (BRG1-associated factor) complex is neuron-specific and critical for synaptic gene expression. Mutations in BAF subunits cause neurodevelopmental disorders, and altered BAF function contributes to neurodegeneration.

CHD (Chromodomain Helicase DNA-binding) proteins including CHD4 (part of the NuRD complex) and CHD5 regulate neuronal gene expression. CHD5 is a tumor suppressor with emerging roles in neurodegeneration.

ISWI family complexes (NURF, CHRAC, NoRC) regulate nucleosome spacing and are involved in heterochromatin maintenance.

Cross-Disease Epigenetic Alterations

Alzheimer's Disease

AD exhibits a characteristic pattern of epigenetic dysregulation involving both global changes and gene-specific alterations: [@dejager2024]

DNA Methylation: Genome-wide studies reveal global hypomethylation in AD cortex and hippocampus, accompanied by locus-specific hypermethylation at genes involved in neuronal signaling, synaptic function, and immune response. The SNX30 and ANK1 genes show consistent hypermethylation in AD brain, correlating with reduced expression. [@smith2018]

Histone Modifications: H3K9ac and H3K4me3 are reduced at synaptic plasticity genes in AD hippocampus, contributing to impaired memory-related transcription. H3K9me3 loss leads to chromatin decondensation and transposable element reactivation. [@shen2024]

5-hydroxymethylcytosine (5hmC): The 5hmC landscape is altered in AD brain, with specific gains at neuronal genes and losses at glial genes. TET enzymes are dysregulated, and 5hmC patterns can serve as biomarkers of disease state. [@zhao2024]

Key target genes in AD:

| Gene | Epigenetic Change | Effect |
|------|-------------------|--------|
| BDNF | Reduced H3K9ac, increased DNA methylation | Decreased neurotrophic support |
| ARC | Reduced H3K9ac | Impaired synaptic plasticity |
| HOMER1 | Reduced H3K9ac | Altered glutamate receptor signaling |
| REST | Altered MeCP2 binding | Dysregulated neuronal survival pathways |
| ANK1 | Hypermethylation | Reduced expression, altered cytoskeleton |
| SNX30 | Hypermethylation | Impaired endosomal function |

Parkinson's Disease

PD epigenetic changes are particularly evident at the SNCA locus, which encodes alpha-synuclein: [@jowaed2010]

SNCA promoter methylation: Paradoxically, while SNCA promoter DNA is hypermethylated in PD patients' brains — a seemingly suppressive mark — SNCA expression is elevated. This apparent contradiction is explained by the finding that the hypermethylation primarily affects intronic regions rather than the promoter, and chromatin accessibility changes dominate the transcriptional output. The H3K9me3 mark is specifically lost at the SNCA locus, correlating with increased transcription.

Mitochondrial epigenetic regulation: PD genes involved in mitochondrial quality control (PARK2/parkin, PINK1) are subject to epigenetic regulation. Environmental factors like paraquat exposure alter DNA methylation at these loci, potentially increasing susceptibility.

Key target genes in PD:

| Gene | Epigenetic Change | Effect |
|------|-------------------|--------|
| SNCA | Loss of H3K9me3, intronic DNA hypermethylation | Increased transcription |
| PARK2 | Promoter hypermethylation | Reduced parkin expression |
| LRRK2 | Altered histone modifications | Variable effects on expression |
| GBA1 | DNA methylation changes | Reduced glucocerebrosidase |
| PINK1 | Hypermethylation | Impaired mitophagy |

ALS and Frontotemporal Dementia

ALS and FTD share considerable epigenetic overlap, particularly in C9orf72-associated cases: [@jones2024]

C9orf72 promoter methylation: Hypermethylation of the C9orf72 promoter is a well-established feature of ALS/FTD patients with hexanucleotide repeat expansions. In some patients, complete promoter methylation silences the expanded allele, paradoxically reducing toxic RNA foci but also potentially reducing normal C9orf72 protein function. The degree of promoter methylation correlates with clinical phenotype — higher methylation associates with earlier onset and longer survival. [@davis2022]

TDP-43 pathology and epigenetics: TDP-43 (encoded by TARDBP) is an RNA-binding protein that also has roles in transcriptional regulation. TDP-43 pathology — the hallmark of ALS and most FTD cases — disrupts its normal chromatin-associated functions, leading to widespread transcriptional dysregulation including aberrant splicing and premature transcription termination. [@sone2023]

FUS and epigenetic regulation: FUS (fused in sarcoma) mutations cause familial ALS and alter chromatin remodeling through interactions with histone acetyltransferases and the BAF complex.

Huntington's Disease

Huntington's disease exhibits distinctive epigenetic changes centered on the mutant HTT gene and its downstream effects: [@lagomarsino2020]

BDNF epigenetic regulation: The BDNF gene is repressed in HD striatum through multiple epigenetic mechanisms including loss of H3K9ac, increased H3K9me3 at its promoter, and DNA hypermethylation. This repression of neurotrophic support contributes to striatal neuron death.

H3K9me3 and heterochromatin loss: Global loss of H3K9me3 and satellite repeat hypermethylation are observed in HD, contributing to genomic instability and transposable element reactivation.

Non-Coding RNA Dysregulation

Non-coding RNAs provide an additional layer of epigenetic-like regulation through post-transcriptional mechanisms. [@sonntag2024]

microRNAs (miRNAs) in Neurodegeneration

miRNAs are small (~22 nucleotide) RNAs that bind target mRNAs and suppress translation or promote degradation. Each miRNA can target hundreds of mRNAs, enabling coordinated regulation of entire gene expression programs.

AD-associated miRNAs:

| miRNA | Target | Effect |
|-------|--------|--------|
| miR-9 | REST, BCL2 | Synaptic dysfunction, apoptosis |
| miR-124 | BCL2, AMPK | Reduced neuronal survival |
| miR-29a/b | BACE1 | Increased amyloid production |
| miR-181c | SPRY2, PTEN | Pro-apoptotic |
| miR-146a | TRAF6, IRAK1 | Promotes neuroinflammation |
| miR-132 | FOXO3A, PTEN | Regulates neuronal survival |

PD-associated miRNAs:

| miRNA | Target | Effect |
|-------|--------|--------|
| miR-7 | SNCA | Neuroprotective (represses alpha-syn) |
| miR-153 | SNCA | Cooperates with miR-7 to suppress |
| miR-124 | BCL2 | Promotes dopaminergic survival |
| miR-133b | PITX3 | Regulates dopamine neuron development |
| miR-34b/c | Parkin, DJ-1 | Mitochondrial dysfunction |

ALS-associated miRNAs:

| miRNA | Target | Effect |
|-------|--------|--------|
| miR-155 | SOCS1, SMAD7 | Pro-inflammatory |
| miR-9 | REST, TDP-43 | Motor neuron dysfunction |
| miR-124 | SOD1 | Affects ALS pathology |
| miR-218 | ALS2, CHCHD10 | Motor neuron degeneration |

Long Non-Coding RNAs (lncRNAs)

lncRNAs are >200 nucleotide transcripts that regulate gene expression through diverse mechanisms — chromatin scaffolding, transcriptional interference, miRNA sponging, and direct interaction with proteins.

NEAT1 (Nuclear Enriched Abundant Transcript 1): NEAT1 forms paraspeckles — nuclear bodies involved in RNA processing, protein sequestration, and gene regulation. NEAT1 is significantly upregulated in AD and ALS brain, representing a compensatory response to proteostatic stress. In ALS, NEAT1 upregulation correlates with TDP-43 pathology.

MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1): MALAT1 regulates alternative splicing of synaptic proteins and is dysregulated in AD. It modulates the expression of multiple synaptic genes including NRXN1 and NLGN1.

TUNA (NCL/TUNA): TUNA maintains pluripotency and neuronal differentiation. Reduced TUNA expression is observed in ALS spinal cord motor neurons, and TUNA mutations cause a juvenile-onset ALS with cerebellar ataxia phenotype.

BDNF-AS: Antisense to BDNF mRNA, BDNF-AS recruits EZH2 to the BDNF promoter, promoting H3K27me3 and silencing BDNF transcription. BDNF-AS is elevated in AD models, contributing to reduced BDNF.

Circular RNAs (circRNAs)

circRNAs are covalently closed RNA molecules produced by back-splicing that function as miRNA sponges, protein scaffolds, and translational templates. Their stability makes them attractive biomarker candidates.

circMAPT: Sponges miR-151-3p, leading to increased MAPT (tau) expression. circMAPT is dysregulated in AD brain and CSF.

circSMARCA5: Regulates neuronal differentiation and is altered in AD. It sponges miR-4492, affecting synaptic gene expression.

circDLGAP4: Reduced in AD brain, sponges miR-134 and regulates RELN expression.

Metabolic Epigenetics: NAD+ and the Epigenome

The availability of metabolic cofactors directly controls epigenetic enzyme activity, creating a direct link between cellular metabolism and gene regulation: [@stilling2017]

SIRT1 (NAD+-dependent Deacetylase)

SIRT1 uses NAD+ as a cofactor to deacetylate histone H4K16ac and non-histone targets including PGC-1alpha, FOXO3, and p53. Through these actions, SIRT1 integrates cellular energy status with gene expression programs governing stress resistance, mitochondrial function, and circadian rhythms.

SIRT1 in AD: SIRT1 expression and activity are reduced in AD hippocampus and cortex. SIRT1 activation promotes microglial A-beta phagocytosis, reduces neuroinflammation, and improves cognitive function. Resveratrol and other SIRT1 activators have shown benefit in AD models, though clinical translation has been challenging due to poor BBB penetration.

SIRT1 in PD: SIRT1 protects dopaminergic neurons from oxidative stress and mitochondrial dysfunction. SIRT1 activation reduces alpha-synuclein toxicity in cell and animal models.

NAD+ precursors as epigenetic therapies: NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and niacin supplementation can boost NAD+ levels and indirectly support SIRT1 activity. Human trials of NAD+ precursors in aging and neurodegeneration are ongoing.

AMPK and Epigenetic Regulation

AMPK (AMP-activated protein kinase) is activated by low energy charge and phosphorylates epigenetic regulators including HDAC5 (promoting its nuclear export) and CREB (regulating its transcriptional activity). AMPK activation improves cognitive function in AD models through epigenetic mechanisms.

Lactate and Histone Lactylation

A breakthrough finding revealed that lactate — produced by glycolysis under hypoxic or Warburg-like conditions — can lactylate histone lysine residues (Kla), particularly H3K18la. [@koppen2023]

Lactylation in neurodegeneration: Microglial cells under pro-inflammatory conditions show elevated histone lactylation, which promotes transcription of wound-healing and homeostatic genes. In AD brain, increased H3K18la is observed in microglia and correlates with disease severity. This represents a novel metabolic-epigenetic link connecting dysregulated glucose metabolism to gene expression changes in neurodegeneration.

One-Carbon Metabolism and Epigenetics

The folate and methionine cycles provide methyl groups for DNA and histone methylation. S-adenosylmethionine (SAM) is the universal methyl donor for methyltransferases. Disruption of one-carbon metabolism — common in aging and neurodegeneration — impairs methylation capacity and alters the epigenetic landscape.

Epigenetic Clock and Brain Aging

The epigenetic clock is a biomarker of biological aging based on DNA methylation patterns at specific CpG sites. Multiple clocks have been developed: [@horvath2018]

Horvath clock (353 CpG sites): Trained on chronological age across multiple tissues, it provides highly accurate age predictions. Epigenetic age acceleration — where biological age exceeds chronological age — is observed in neurodegenerative disease brain tissue.

PhenoAge (513 CpG sites): Trained on clinical biomarkers of aging rather than chronological age. Better correlates with health outcomes including mortality and cognitive decline.

GrimAge (via DNA methylation proxy): Based on methylation of smoking-related CpGs and plasma proteins. Strongest predictor of all-cause mortality.

DunedinPACE: Developed from the Dunedin cohort, measures the pace of aging based on 19 biomarkers tracked over time. Captures individual variation in aging rate.

In Alzheimer's disease, brain tissue shows an average epigenetic age acceleration of 2-4 years, with greater acceleration in the prefrontal cortex than in the cerebellum. [@brown2022] The acceleration correlates with neurofibrillary tangle burden, amyloid plaque density, and cognitive impairment at time of death. Epigenetic age acceleration predicts conversion from MCI to AD dementia and may serve as a stratification biomarker.

Transposable Element Reactivation

Loss of heterochromatin with aging and neurodegeneration leads to derepression of transposable elements (TEs), which constitute ~45% of the human genome: [@taylor2021]

LINE-1 (Long Interspersed Nuclear Element-1): Autonomous retrotransposons that can copy themselves via reverse transcription. LINE-1 mobilization is restricted in somatic cells but becomes more active in neurons during aging and in AD brain. Somatic LINE-1 insertions in neurons can disrupt gene expression and genomic stability.

ERVs (Endogenous Retroviruses): Human endogenous retroviruses (HERVs), particularly HERV-K (HML-2), are upregulated in ALS, AD, and MS brain. HERV-K RNA and protein can be detected in neurons and glia, and some studies suggest they may contribute to neuroinflammation through pattern recognition receptor activation.

ALU elements: Non-autonomous SINE elements that are also derepressed in AD brain. They can be transcribed and potentially influence gene expression through RNA-based mechanisms.

Epigenetic Regulatory Pathway Diagram

The following diagram illustrates the interconnected epigenetic regulators and their downstream effects on neurodegeneration:

Therapeutic Strategies Targeting the Epigenome

Epigenetic therapies offer the potential to reverse disease-associated transcriptional changes rather than just targeting downstream pathology: [@fan2025]

HDAC Inhibitors

| Drug | Class | Disease | Mechanism | Status |
|------|-------|---------|-----------|--------|
| Vorinostat (SAHA) | Pan-HDAC (I/II) | ALS | Increases H3K9ac at synaptic genes | Phase 1 (NCT04727554) |
| Valproic acid | Class I HDAC | AD | Increases H3K9ac, anti-apoptotic | Phase 2 completed, neutral |
| Romidepsin | Class I HDAC | PD | Increases BDNF expression | Preclinical |
| Tubastatin A | HDAC6-selective | AD/PD | Increases alpha-tubulin acetylation | Preclinical |
| Entinostat (MS-275) | HDAC1/2/3 | AD | Increases H3K9ac at memory genes | Preclinical |

[@gao2024] [@ibrahim2025]

BET Bromodomain Inhibitors

| Drug | Target | Disease | Mechanism | Status |
|------|-------|---------|-----------|--------|
| JQ1 | BRD4 | AD | Reduces amyloid, tau, neuroinflammation | Preclinical |
| I-BET151 | BET | ALS/FTD | Reduces C9orf72 toxicity | Preclinical |
| ABBV-744 | BD2-selective BET | AD | Lower toxicity than pan-BET | Preclinical |

[@chen2021]

DNA Methylation Modulation

| Strategy | Agent | Disease | Mechanism | Status |
|---------|-------|---------|-----------|--------|
| DNMT inhibition | 5-azacytidine | AD | Reverses hypermethylation | Preclinical |
| DNMT inhibition | Decitabine | PD | Normalizes SNCA methylation | Preclinical |
| Methyl donor | SAMe | AD/PD | Supports normal methylation | Supplements |
| TET activation | Vitamin C | AD | Enhances demethylation | Phase 2 |

[@schneider2024]

miRNA-Based Therapies

| Strategy | Target miRNA | Disease | Approach | Status |
|----------|-------------|---------|---------|--------|
| miRNA mimic | miR-29a | AD | Restore BACE1 repression | Preclinical |
| miRNA mimic | miR-124 | PD | Promote neuronal survival | Preclinical |
| Antagomir | miR-7 | PD | Increase alpha-syn suppression | Preclinical |
| Antagomir | miR-155 | ALS | Reduce inflammation | Preclinical |

[@liu2023]

CRISPR-Based Epigenetic Editing

Precision epigenetic tools using catalytically dead Cas9 (dCas9) fused to epigenetic modifiers enable locus-specific editing: [@adachi2024]

• dCas9-TET1: Targeted DNA demethylation at specific promoters
• dCas9-DNMT3A: Targeted de novo methylation
• dCas9-p300: Targeted H3K27ac deposition at enhancers
• dCas9-LSD1: Targeted demethylation of H3K4me1/2

NAD+ Boosters as Epigenetic Modulators

| Supplement | Target | Disease | Mechanism | Status |
|-----------|-------|---------|-----------|--------|
| Nicotinamide riboside (NR) | NAD+ | AD | SIRT1/2/3 activation | Phase 2 (NCT05065597) |
| NMN (nicotinamide mononucleotide) | NAD+ | PD | SIRT1 activation, mitochondrial support | Phase 1/2 |
| Resveratrol | SIRT1 | AD | H4K16ac restoration | Phase 3 (mixed results) |

Biomarkers

Epigenetic changes can serve as accessible biomarkers for diagnosis, prognosis, and treatment monitoring: [@park2021]

| Biomarker | Type | Disease | Source | Utility |
|-----------|------|---------|--------|---------|
| 5mC at ANK1 | DNA methylation | AD | Blood, brain | Diagnostic |
| 5mc global level | DNA methylation | AD/PD | Blood | Prognostic |
| H3K9ac | Histone modification | AD | Peripheral blood mononuclear cells | Monitoring |
| miR-29a | miRNA | AD | CSF, blood | Diagnostic |
| miR-7 | miRNA | PD | Blood, brain | Diagnostic |
| miR-155 | miRNA | ALS, FTD | CSF, blood | Prognostic |
| miR-124 | miRNA | PD, ALS | Blood | Disease progression |
| Epigenetic age acceleration | Clock | AD, PD | Blood | Risk stratification |
| NEAT1 | lncRNA | AD, ALS | CSF | Diagnostic |

Cross-Disease Comparison: Epigenetic Alterations

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS / FTD | Huntington's Disease |
|---------|--------------------|---------------------|-----------|-------------------|
| Global DNA methylation | Hypomethylation | Variable | Hypomethylation | Hypomethylation |
| Key DM gene | ANK1, SNX30 | SNCA, PARK2 | C9orf72 promoter | BDNF |
| H3K9me3 | Reduced | Reduced at SNCA | Reduced | Reduced |
| H3K9ac | Reduced at synaptic genes | Reduced | Reduced | Reduced at BDNF |
| H3K27ac | Reduced | Reduced | Reduced | Variable |
| 5hmC | Altered landscape | Altered | Less studied | Reduced |
| Reader affected | MeCP2, HDAC2 | HDAC6, BET | TDP-43 (indirect) | MeCP2 |
| TE reactivation | LINE-1, ALU | HERV-K | HERV-K | LINE-1 |
| Epigenetic age accel. | 2-4 years | 1-3 years | 2-5 years | 2-4 years |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Sirtuin Signaling Pathway](/mechanisms/sirtuin-signaling-pathway)
• [DNA Damage Response](/mechanisms/dna-damage-response)
• [NAD+ Signaling in Neurodegeneration](/mechanisms/nad-signaling-neurodegeneration)
• [Non-Coding RNA in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
• [Cellular Senescence](/mechanisms/cellular-senescence)
• [Protein Quality Control Network](/mechanisms/protein-quality-control-network)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
• [Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
• [TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TET2
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Temporal TET2-Mediated Hydroxymethylation Cycling](/hypothesis/h-a90e2e89) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: TET2

Related Analyses:

• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic Dysregulation in Neurodegeneration discovered through SciDEX knowledge graph analysis: